Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375

Dow Jones06-24

By Anvee Bhutani

Verastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations.

The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile.

Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company.

Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle.

The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca.

Verastem expects to provide another update on the program later this year.

Write to Anvee Bhutani at anvee.bhutani@wsj.com

(END) Dow Jones Newswires

June 23, 2026 16:25 ET (20:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645585906?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645585906","market":"other","top_or_hot":-1,"title":"Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Anvee Bhutani \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n</p>\n<p>\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n</p>\n<p>\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n</p>\n<p>\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n</p>\n<p>\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n</p>\n<p>\n  Verastem expects to provide another update on the program later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Reports Positive Early Data for KRAS Cancer Drug VS-7375\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-24 04:25</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Anvee Bhutani \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n</p>\n<p>\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n</p>\n<p>\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n</p>\n<p>\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n</p>\n<p>\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n</p>\n<p>\n  Verastem expects to provide another update on the program later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4085","symbol_name":"互动家庭娱乐","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645585906","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645585906","pubTimestamp":1782246300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations.The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile.Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company.Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle.The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca.Verastem expects to provide another update on the program later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4085":"互动家庭娱乐","VS":"Versus Systems Inc.","VSTM":"Verastem","BK4139":"生物科技"},"translate_title":"Verastem报告KRAS抗癌药物VS-7375的积极早期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VS":1.5,"VSTM":1.5},"content_text":"By Anvee Bhutani \n\n\n \n\n\nVerastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n\n\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n\n\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n\n\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n\n\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n\n\n  Verastem expects to provide another update on the program later this year. \n\n\n \n\n\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645585906","isCrawlerRequest":true}